Gliptins: a safe and effective treatment of diabetes mellitus

Česká verzia

Authors: Jiří Slíva ^1,2; Martin Prázný ³
Authors place of work: Farmakologický ústav 2. LF UK Praha, přednosta doc. MUDr. Martin Votava, Ph. D. ¹; Ústav farmakologie 3. LF UK Praha, přednosta prof. MUDr. Jan Bultas, CSc. ²; III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA ³
Published in the journal: Vnitř Lék 2014; 60(9): 772-774
Category:

Summary

Gliptins are well recognized substances modulating incretin system via inhibition of dipeptidylpeptidase IV. Their efficacy was demonstrated both in monotherapy and in combination with metformin, where they act synergistically. Hence, a better control of diabetes might be assumed. This short article aims to show current trends in their prescription in the Czech Republic.

Key words:
diabetes mellitus – dipeptidylpeptidase IV – gliptins – oral antidiabetics

Zdroje

1. Li L, Shen J, Bala MM et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014; 348: g2366. Dostupné z DOI: <http://doi: 10.1136/bmj.g2366>.

2. Egan AG, Blind E, Dunder K et al. Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med 2014; 370(9): 794–797.

3. Panagoulias GS, Doupis J. Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. Patient Prefer Adherence 2014; 8: 227–236.

4. Koliaki C, Doupis J. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology. Adv Ther 2012; 29(12): 993–1004.

5. Guarino E, Nigi L, Patti A et al. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother 2012; 13(9): 1377–1384.

6. Benford M, Milligan G, Pike J et al. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther 2012; 29(1): 26–40.